Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Benitec Biopharma ( (BNTC) ) has shared an update.
On December 1, 2025, Benitec Biopharma Inc. held its virtual 2025 Annual Meeting of Stockholders, where 85.06% of the company’s shares were represented. The meeting resulted in the election of directors, ratification of an independent accounting firm, and approval of executive compensation, with all proposals receiving the necessary votes for approval.
The most recent analyst rating on (BNTC) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.
Spark’s Take on BNTC Stock
According to Spark, TipRanks’ AI Analyst, BNTC is a Neutral.
Benitec Biopharma’s stock score is primarily driven by weak financial performance, reflected in large net losses and negative cash flow. The technical outlook is bearish, and valuation concerns arise from a negative P/E ratio. However, the recent positive corporate event provides a glimmer of potential growth, slightly boosting the score.
To see Spark’s full report on BNTC stock, click here.
More about Benitec Biopharma
Benitec Biopharma Inc. operates in the biopharmaceutical industry, focusing on developing innovative therapeutics based on its proprietary DNA-directed RNA interference (ddRNAi) technology, which aims to address unmet medical needs in various diseases.
Average Trading Volume: 144,014
Technical Sentiment Signal: Sell
Current Market Cap: $414.1M
For a thorough assessment of BNTC stock, go to TipRanks’ Stock Analysis page.